Latest News and Press Releases
Want to stay updated on the latest news?
-
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Peripheral Arterial Disease (PAD) Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global...
-
Wilmington, Delaware, United States, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - Advancements in endovascular techniques and optimal revascularization techniques are some...
-
June 3, 2021 Results show that first-of-its-kind device has a sustained treatment effect and a positive impact on quality of life Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,...
-
MELBOURNE, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has...
-
MELBOURNE, Australia, March 12, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that...
-
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC...
-
CALGARY, Alberta, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing...
-
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two...
-
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and...
-
CALGARY, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that is has completed refinements to its...